Online inquiry

IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5516MR)

This product GTTS-WQ5516MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL17A&IL17F gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002190.3; NM_052872.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605; 112744
UniProt ID Q16552; Q96PD4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5516MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14071MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-3918
GTTS-WQ13176MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-04518600
GTTS-WQ7114MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FE 999301
GTTS-WQ7446MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GBR500
GTTS-WQ5905MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CIM 331
GTTS-WQ14954MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA SHR-1210
GTTS-WQ15748MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA VX-15
GTTS-WQ12832MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ONC-005
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW